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Abstract
Objective
To compare changes in gene expression by microarray from subcutaneous adipose tissue
from HIV treatment naïve patients treated with efavirenz based regimens containing
abacavir (ABC), tenofovir (TDF) or zidovidine (AZT).
Design
Subcutaneous fat biopsies were obtained before, at 6- and 18–24-months after treatment,
and from HIV negative controls. Groups were age, ethnicity, weight, biochemical profile,
and pre-treatment CD4 count matched. Microarray data was generated using the Agilent
Whole Human Genome Microarray. Identification of differentially expressed genes and ge-
nomic response pathways was performed using limma and gene set enrichment analysis.
Results
There were significant divergences between ABC and the other two groups 6 months after
treatment in genes controlling cell adhesion and environmental information processing, with
some convergence at 18–24 months. Compared to controls the ABC group, but not AZT or
TDF showed enrichment of genes controlling adherence junction, at 6 months and 18–24
months (adjusted p<0.05) and focal adhesions and tight junction at 6 months (p<0.5).
Genes controlling leukocyte transendothelial migration (p<0.05) and ECM-receptor interac-
tions (p = 0.04) were over-expressed in ABC compared to TDF and AZT at 6 months but not
at 18–24 months. Enrichment of pathways and individual genes controlling cell adhesion
and environmental information processing were specifically dysregulated in the ABC group
in comparison with other treatments. There was little difference between AZT and TDF.
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Conclusion
After initiating treatment, there is divergence in the expression of genes controlling cell ad-
hesion and environmental information processing between ABC and both TDF and AZT in
subcutaneous adipose tissue. If similar changes are also taking place in other tissues in-
cluding the coronary vasculature they may contribute to the increased risk of cardiovascular
events reported in patients recently started on abacavir-containing regimens.
Introduction
Antiviral therapies for HIV infection have been associated with abnormalities in serum lipids,
[1] an increased incidence of type 2 diabetes mellitus,[2] and increased cardiovascular disease.
[3–7] However the metabolic and adipose tissue effects of antiretroviral regimens are not the
same with all regimens.[8] Regimens containing tenofovir disoproxil fumarate (TDF) have
demonstrated less effect on serum lipids and subcutaneous adipose tissue than those contain-
ing zidovidine (AZT).[9] Moreover treatment with abacavir-containing regimens has been
associated with increased risk of cardiovascular disease in some studies [10–14] but not others
[15–18]
We have previously reported changes in the expression of genes controlling lipid metabo-
lism and mitochondrial respiratory chain in biopsies taken from patients 6 and 18–24 months
after starting antiretroviral regimens containing different nucleoside analogue regimens
combined with efavirenz. [19,20] Here we report results from a microarray study performed
on subcutaneous adipose tissue biopsies from the same study.
Patients and Methods
Details of the patients have been previously reported and the design of the study is summarised
in Fig. 1. [19,20] Briefly, the study was undertaken in two parts. In the first part iliac crest fat
biopsies were performed on 32 HIV-positive patients naïve to antiretroviral therapy who were
randomised to receive either zidovidine (AZT)/lamivudine (3TC n = 15) in fixed dose prepara-
tion or tenofovir (TDF)/emitricitabine (n = 17), again in fixed dose preparation. Both groups
also took efavirenz (EFV). All patients underwent extensive biochemical screening, tests of
body fat distribution (whole body DEXA and abdominal CT scans) and iliac crest biopsy
under local anaesthesia, as previously described. [19] Tests were performed before starting
treatment, at six months and again at 18–24 months after initiating therapy. 15 HIV negative
controls underwent similar investigations.
In the second non-randomised part of the study patients who were on their initial antiretro-
viral regimen containing abacavir (ABC) and 3TC in fixed-drug combination plus EFV for
6 months (n = 8) or 18–24 months (n = 11) were also tested in a similar way. Patients and con-
trols from both parts of the study were matched for age, ethnicity, gender, weight, and BMI.
None had ever had an AIDS defining disease. All three HIV groups were also matched with re-
gards to pre-treatment CD4 count, viral load [19,20] and family history of diabetes and cardio-
vascular disease. The median age (range) for the controls was 37 (22–55), for AZT 33 (22–62),
for TDF 35.5 (23–53) and for ABC 37 (21–62). The median (IRQ) CD4 count before treatment
were AZT 187 (153–268), TDF 234 (163–253) and ABC 215 (75–306). Pre-treatment viral
loads log10 (IRQ) were 5.1 (4.4–5.7), 4.6 (4.2–5.3) and 4.5 (4.4–4.9) respectively for AZT,
TDF and ABC. All but two patients (both on AZT) had undetectable viral load when tested at
Abacavir Regimen and Adherence Junction Genes
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6 month following treatment (209 and 109,638 copies/ml) but all had undetectable viral loads
at 18–24 m. Both admitted to poor compliance. None developed any clinical evidence of lipo-
dystrophy during the period of study and post treatment weight, BMI, DEXA and abdominal
CT results were not significantly different between groups at both time points after treatment.
Serum lipids, fasting glucose and other parameters were similar between groups at each time
point.[19,20]
Samples for microarray were available from 103 biopsy specimens (Fig. 1). There was no
significant difference in weight, BMI, central and peripheral fat, and visceral and subcutaneous
fat, or blood biochemistry in the patients undergoing microarray study at any time point.
Microarray methods
RNA was extracted for microarray and array data generated using a Qiagen RNeasy Lipid
Tissue Mini Kit. Total RNA was converted into labeled cDNA using the WT-Ovation Pico
RNA Amplification System and samples were hybridized to an Agilent Whole Human Genome
Microarray 4×44K (AMADID 014850, Agilent Technologies). The Agilent arrays were scanned
with the Agilent Technologies DNAMicroarray Scanner G2505C with default settings.
Figure 1. Flow chart of study design. Rx = treatment; AZT = zidovdine and lamivudine; TDF = tenofovir and emtricitabine; ABC = abacavir and
lamivudine. All three groups were also taking efavirenz; n = number of samples available for microarray at each time point.
doi:10.1371/journal.pone.0117164.g001
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Scanned images were extracted and initial quality control performed in Agilent Feature
Extraction (AFE) software version 10.7.3.1. Additional quality assessment was performed
using the R arrayQualityMetrics package.[21] As no major experimental problems could be
detected, all microarrays were included in subsequent analysis steps. The dataset was read into
R and processed using the Agi4x44PreProcess package with options to use the AFE Processed
Signal as foreground signal and BG Used signal as background adjusted signal.[22] The data
were then normalized by the quantilemethod using the limma function normalize Between
Arrays.[23] Probeset filtering was performed using the Agi4x44PreProcess filter method using
AFE provided flags to identify features with quantification errors of the signal, reducing the
45,015 features on the Agilent Whole Human Genome Microarray 4×44K array by 34%, or
15,339 features. Residual technical batch effects were corrected using the ComBat method
implemented in the SVA R package.[24]
Since patients were not randomised to the ABC treatment all samples were treated as
unrelated. Gene expression differences between treatment arms were assessed using the linear
modeling features implemented in the limma package in R[25]. Multiple testing across con-
trasts was performed using the limma global method with Benjamini-Hochberg approach for
control of false discovery rate (FDR). Gene set enrichment analysis of GO terms and KEGG
pathways was performed using the conditional hypergeometric test implemented in the
GOstats R package[26]. Statistical significance of gene set enrichment was performed using the
Benjamini-Hochberg correction method implemented in the EMA R package [27]. Microarray
data have been submitted to the Gene Expression Omnibus (GEO) and are available under
NCBI accession number GSE 62117
Ethics Statement
The study was approved by the South Birmingham Research Ethics Committee (Reference
05/Q2707/40) and the Medicines and Healthcare Products Regulatory Agency—MHRA
(Eudract number 2005/004021-26). All patients signed an informed consent to participate in
the study.
Results
Global Gene Expression
Multi-dimensional scaling (MDS) on all 103 samples was performed using profile level gene
expression data from individual samples to see if subjects group according to treatment, time
points or both. Distances were plotted using the limma plotMDS function with default parame-
ters. Along the first dimension there was a clear separation of samples by samples time whereas
in the second dimension the greatest distance was between the ABC treatment groups (6 m
and 18–24 m) versus the other treatment groups including the untreated patients and the
controls (Fig. 2).
Groups of differentially expressed genes were next generated using the R/Bioconductor
limma library. Statistical criteria for identification of differentially expressed genes were FDR
adjusted P< 0.01 and fold change greater than 2.0. The cross sectional comparisons Table 1
showed the difference between groups was particularly striking at 6 months with ABC showing
4,185 differentially expressed genes (DEGs) compared to controls while the number of DETs
for AZT and TDF were 895 and 381 respectively. Gene expression between the three groups at
18–24 months appear to have converged. At 18–24 m there were only 5 DETs between AZT
and TDF, 88 between AZT and ABC and 251 between TDF and ABC (Table 1).
Abacavir Regimen and Adherence Junction Genes
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Gene enrichment analysis
a. Comparison with controls
To gain mechanistic insight statistical list DEGs for each treatment contrast were tested for as-
sociation to Gene Ontology (GO) terms and KEGG terms using the conditional
Figure 2. Themulti-dimensional scaling plot (MDS) shows that by and large ABC 6 and ABC 18–24 samples are separated from other samples in
the study.Distances in the plot represent root-mean-square deviation (Euclidean distance) for the top 500 genes that best distinguish those samples.
doi:10.1371/journal.pone.0117164.g002
Table 1. Differentially expressed sequences between groups at 6 months and 18–24 months.
AZT 6 TDF6 ABC 6 AZT 18–24 TDF 18–24 ABC 18–24
Control 895 381 4146 3255 3322 4185
AZT 6 90 3434
TDF 6 4288
AZT 18–24 5 88
TDF 18–24 251
doi:10.1371/journal.pone.0117164.t001
Abacavir Regimen and Adherence Junction Genes
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hypergeometric test algorithm implemented in R package GOStats (Falcon and Gentleman,
2007). Statistical significance of gene set enrichment was performed using the Benjamini-
Hochberg correction method. Selected KEGG pathways showing over-representation in the
three treatment groups compared to the controls are shown in the (Table 2).
Adherence junction was significantly enriched compared to controls in the ABC group
at both time points but not in the other two treatment groups. Six months after treatment
24 genes were up-regulated and 8 genes were down regulated compared to controls in the
ABC group (<0.01). At 18–24 months after treatment the corresponding figures were 22 up-
regulated and 7 down regulated (p<0.01) Individual adherence junction genes significantly
up-regulated or down-regulated in the ABC treatment arm compared to controls are tabulated
in Table 3.
Focal adhesions and tight junctions were also significantly enriched compared to the con-
trols in the ABC treated group at 6 months but not in the other treatment groups. (Table 2)
GO terms significantly enriched with ABC but not the other treatment groups at 6 months
after treatment include cell adhesion (GO:7155, OR 1.3, p = 0.04), apical junction assembly
(GO:43297, OR 2.8, p = 0.03), cell-cell junction assembly (GO:7043, OR 1.8, p = 0.04), cell-cell
junction organisation (GO:45216, OR 1.4, p = 0.04), and cell matrix adhesion (GO:7160,
OR1.7, p = 0.04). At 18–24 months Go terms significantly enriched with ABC treatment alone
include cell-cell—junction assembly (OR 1.4, p = 0.04), cell-cell signaling (GO:726, OR 1.8,
p<0.002) and for ABC and TDF signaling (GO:23052, OR1.2, p = 0.003).
b. Comparison between treatment arms at each time point
We next performed enrichment analysis using statistical list of DEG from contrast of the three
different treatment regimens at 6 and 18–24 months (excluding the HIV negative samples) in a
cross sectional analysis. A Venn analysis was performed for each time point and Volcano plots
Table 2. Selected KEGG gene pathways relating to cell communication and environmental information processing that were signiﬁcantly
enriched compared to HIV negative controls.
Time Term KID Adjusted P OR Expected count Observed count
Control—ABC 6 m ECM-receptor interaction 4512 0.036 1.80 16 25
Focal adhesion 4510 0.036 1.40 41 53
Tight junctions 4530 0.043 1.50 24 32
Adherence Junction 4520 0.043 1.62 16 23
Control—ABC 18–24 m Wnt signalling pathway 4310 0.045 1.49 27.1 36
Adherence Junction 4520 0.045 1.65 16.2 23
ECM-receptor interaction 4512 0.046 1.65 16.2 23
Control—AZT 6m Cytokine-cytokine receptor interaction 4060 0.03 3.02 2.17 6
Control – AZT 18–24 m Neuroactive ligand-receptor interaction 4080 <0.0001 2.78 26.1 54
Cytokine-cytokine receptor interaction 4060 0.019 1.61 25 36
ECM-receptor interaction 4512 0.034 1.78 11.5 18
Control—TDF 6 m Cytokine-cytokine receptor interaction 4060 0.038 6.90 0.58 3
Control—TDF 18–24 m Neuroactive ligand-receptor interaction 4080 <0.0001 2.67 25 51
Cytokine-cytokine receptor interaction 4060 0.01 1.76 24 37
ECM-receptor interaction 4512 0.021 2.03 11.1 19
VEGF signalling pathway 4370 0.029 1.88 10.4 17
WNT signalling pathway 4310 0.04 1.54 18.5 26
KID = Kegg identity; OR = odds ratio; Time = time after treatment
doi:10.1371/journal.pone.0117164.t002
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were created filtering by fold change>1.5 and Benjamini-Hochberg corrected p-value<0.05 at
6 months and 18–24 months (Fig. 3).
Six months after treatment enrichment of gene pathways involved with WNT signalling
and leukocyte transendothelial migration were seen in ABC compared to patients receiving
TDF and neuroactive ligand receptor interaction, leukocyte transendothelial migration and
cytokine-cytokine receptor interactions compared to patients receiving AZT (Table 4).
KEGG pathways significantly over expressed when ABC was compared with the combined
other two treatment groups at six months (intersection in Venn analysis) included ECM
Table 3. Expression of genes controlling adherence junction in ABC treated group in comparison with controls at 6 months and 18–24 months
after treatment.
Time on
treatment
Upregulated Down regulated Adjusted p
value
6 months ACTN1, CSNK2A1, CTNNA1, CTNNB1, CTNND1, EGFR, EP300, FGFR1,
INSR, IQGAP1, NLK, PTPN1, PTPRB, PTPRF, PTPRJ, PTPRM, RHOA,
SMAD2, SORBS1,TCF7L1, TCF7L2, TGFBR1, TJP1,VCL
CLDN3, CLDN4, CLDN5, MAP3K3,
PVRL1, RAC2, SNAI1, SNAI2,
– <0.01–
<0.0001
18–24 months ACTN1, CSNK2A1, CTNNA1, CTNNB1, EGFR, FGFR1, INSR, IQGAP1,
MAP3K3, NKL, PTPN1, PTPRB, PTPRF, PTPRJ, PTPRM, RHOA, SMAD2,
SORBS1, TCF7L2, TGFBR1, TJP1,VCL
CLDN3, CLDN4, CLDN5, MAP3K3,
RAC2, SNAI1, SNAI2
<0.01–
<0.0001
ACTN1 = actinin, alpha 1; CSNK = casein kinase; CLDN = claudin, CTNN = catenin (cadherin-associated protein); EGFR = epidermal growth factor
receptor, EP300 = E1A binding protein p300; FGRF1 = ﬁbroblast growth factor receptor 1; INSR = insulin receptor; IQGAP 1 = IQ motif containing
GTPase activating protein 1; MAP3K7 = mitogen-activated protein kinase kinase kinase 7; MLLT4 = myeloid/lymphoid or mixed-lineage leukemia
(trithorax homolog, Drosophila); translocated to, 4; NLK = nemo-like kinase; PTPRB, PTPRF, PTPRFJ, or PTPRFM = protein tyrosine phosphatase,
receptor B, F, J, or M; PVRL 1 = poliovirus receptor-related 1 (herpesvirus mediator C); RAC2 = ras-related C3 botulinum toxin substrate; RHOA = ras
homolog family member A; SMAD = SMAD family member; SNAI1 and SNAI2 = snail family zinc ﬁnger; SORBS1 = sorbin and SH3 domain containing 1
and 2; TCF7L1 and TCF7L2 = transcription factor 7-like; TGFBR = transforming growth factor 1 and 2, beta receptor; VCL = vinculin.
doi:10.1371/journal.pone.0117164.t003
Figure 3. Volcano plot showing significance versus fold changes in the y- and x-axis respectively for
the three treatment groups at 6 months on top row (a-c) and 18months on bottom row (d-f). For each
comparison the first term is the numerator and the second denominator.
doi:10.1371/journal.pone.0117164.g003
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receptor interaction, leukocyte transendothelial migration, tight junction, focal adhesion,
WNT signalling, and cell adhesions (p<0.02).
Go terms over represented in ABC compared to AZT treatments at 6 months include signal-
ling (GO:23052, OR1.3, p = 0.0003), cell-cell signalling (GO:726, OR 1.7, p = 0.003). Most of
the above pathways are involved with cell processes and cell communication (adherence junc-
tion, tight junction, gap junction, focal adhesion -or environmental information processing
(WNT signalling, ECM receptor interaction, neuroactive ligand interactions, cell adhesion
molecules, leukocyte transendothelial migration).
The differences in the expression of genes relating to tight junctions and gap junction
were particularly apparent between ABC and TDF at 6 m. Compared to TDF, 27 ABC genes
controlling tight junctions were significantly up-regulated and 10 down-regulated (p<0.01).
For gap junction genes the corresponding numbers were 19 up-regulated and 8 down regulated
(p = 0.01). Similarly at 6 months compared to TDF and AZT 12 and 13 ABC genes respectively
controlling AJ were up-regulated and 8 and 6 genes down-regulated (p<0.01) while at 18–
24 months only one gene in each treatment groups was significantly up-regulated and none
down-regulated.
At 18–24 months there were insufficient genes for a KEGG pathways or GO term gene
enrichment analysis.
c. Comparison with HIV treatment naïve
Enrichment analysis was next performed using statistical list of DEG in the three treatment
groups and HIV infected treatment naïve subjects. The AZT and TDF pre-treatment samples
were combined (n = 31) to form the HIV treatment naive group. These were then contrasted
with the three treatment groups at 6 m and 18–26 months using limma R/Bioconductor limma
library. A Venn analysis was performed for each time point and the unique gene sets expressed
were tested for over representation analysis of KEGG pathways and GO-terms using the stan-
dard Hypergeometric test.
Significant number of genes were only available for a comparions between treatment groups
six months after treatment, but not at the later time point. There was enrichment of the MAPK
signalling pathway for ABC group compared to HIV treatment naïve patients (p<0.05) which
was not seen with the other two groups. None of the pathways relating to environmental pro-
cessing or signal transduction was enriched in the TDF and AZT treatment groups.
d. Individual gene analysis
In view of the findings showing enrichment of pathways relating to endothelial function we ex-
amined a number of genes relating to endothelial adhesion molecules some of which that had
previously been reported to be affected by HIV and its treatment as well as some genes involved
Table 4. Selected KEGG gene pathways overrepresented in a cross sectional comparison of ABC versus AZT and TDF.
Time Pathway KID Adj p value OR Expected count Observed count
ABC-TDF 6 m Leukocyte transendothelial migration 4670 0.03 1.6 22.3 32
WNT signalling pathway 4301 0.01 1.8 27.2 37
ECM-receptor interaction 4512 0.04 1.6 16.3 23
ABC-AZT 6m Neuroactive ligand receptor interaction 4080 <0.0001 2.6 20.1 48
ECM-receptor interaction 4512 0.02 1.9 12.3 20
Leukocyte transendothelial migration 4670 0.04 1.7 12.1 19
KID = KEGG pathway ID; OR = odds ratio; Time = months on treatment; adj = adjusted
doi:10.1371/journal.pone.0117164.t004
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with tight junction, adherence junction, leukocyte transendothelial migration, and cytokine-cy-
tokine receptor interaction. As can be seen (Table 5) there was over expression of some genes
with ABC treatment in comparison with AZT and TDF. Differences between the three groups
disappeared in all but one of the genes examined at 18–24 months.
Moreover, when we performed enrichment analysis against the GO term ‘biological adhe-
sions’ (GO:22610) compared to ABC six months after treatment, of the 39 genes expressed,
21 genes in the TDF group and 12 genes in the AZT group were either significantly up-or
down regulated (p<0.05). There was no significant difference when AZT and TDF were com-
pared at 6 months. However at 18 m the three regimens had converged such that significant
enrichment was only seen in two genes for TDF and one gene for AZT compared to ABC, with
the two latter treatment groups again showing no difference when compared against one an-
other. A similar difference was observed when the three treatment groups were compared with
controls with 29 genes in GO term ‘biological adhesions’ registered as significant at 6 months
for ABC against none for the other two groups while the number of genes being significantly
Table 5. Expression of selected genes involved with endothelial cell adhesion molecules, tight junction and adherence junction.
Gene ABC 6m vs cont ABC 18–24m vs cont ABC 6m vs
AZT 6m
ABC 6m vs
TDF 6m
ABC 18–24m vs
AZT 18–24m
ABC 18m vs
TDF 18–24m
Pathway
ICAM 1 1.5 p = 0.008 1.7 p = 0.001 NS NS NS NS CAM
ICAM 2 NS NS NS 1.9 p = 0.01 NS NS CAM
ICAM 4 −1.9 p<0.0001 −1.9 p<0.0001 −1.0 p = 0.5 −1.3 p = 0.005 NS NS CAM
ICAM5 −3.2 p<0.0001 −2.6 p<0.0001 −2.2 p<0.0001 −2.8 p<0.0001 NS NS CAM
TICAM1 −3.0 p<0.0001 −2.2 P<0.0001 −1.7 p = 0.002 −2.0 p<0.0001 NS NS TLR, NFkB
TICAM2 3.0 p<0.0001 2.8 p<0.0001 NS 2.0 p<0.0001 NS NS TLR, NFkB
SELPLG −2.6 p<0.0001 −2.0 p<0.0001 −1.7 p = 0.001 −2.2 p<0.0001 NS NS CAM
CD40 −2.2 p<0.0001 −1.9 p<0.0001 −2.1 p<0.0001 2.7 p<0.0001 NS NS CAM, CCR, NFkB
JAM-2 2.9 p = 0.0005 2.6 p = 0006 NS 1.8 p = 0.005 NS NS TJ, LTM
ITGB-1 2.2 P<0.0001 1.9 p<0.0001 1.6 p = 0.01 2.0 p = 0.002 NS NS LTM
VAPA 1.1 p = 0.001 1.2 p = 0.001 1.2 p = 0.002 1.2 p = 0.0005 NS NS TJ
PPP2R4 −1.7* p<0.0001 −1.4** p = 0.0002 −1.7 p = 0.001 −1.9 p<0.0001 NS NS TJ
CLDN3 −2.0 p<0.0001 −2.2 p<0.0001 −1.5 p = 0.001 −2.0 p<0.0001 NS NS CAM, AJ, TJ
CLDN 4 −1.9 p<0.0001 −1.6 p<0.0001 −2.0 p = 0.003 −2.2 p<0.0001 NS NS CAM, TJ, LTM
CLDN5 −2.2 p<0.0001 −1.5 p<0.0001 −1.7 p<0.0001 −2.0 p<0.0001 NS NS CAM, AJ, TJ, LTM
CTNNA1 1.8 p = 0.001 1.8 p = 0.0004 1.6 p = 0.01 1.9 p = 0.001 NS NS AJ, TJ, AJ, LTM
CTNNB1 1.5 p = 0.03 1.8 p = 0.002 1.8 p = 0.0006 1.6 p = 0.005 1.6 p = 0.005 NS AJ, TJ, LTM
ERBB2 −2.4 p<0.0001 −2.8 p<0.0001 −1.8 p<0.0004 −2.3 p<0.0001 NS NS AJ, TJ
MLLT4 −2.3 p = 0.002 −2.0 p = 0.0004 −2.4 p = 0.001 −2.8 p = <0.0001 NS NS AJ, LTM
Results are shown as fold change of ABC treatment versus other treatment groups. Minus sign denotes down regulation of ABC compared to comparison
treatment. P = adjusted signiﬁcance; ICAM = intracellular adhesion molecule; SELPLG = selectin P ligand; CD40 = TNF receptor superfamily member 5
(CD40); transcript variant 1; JAM = junction adhesion molecule; ITGB1 = integrin, beta 1 (ﬁbronectin receptor, beta polypeptide, antigen CD29 includes
MDF2, MSK12);VAPA = Homo sapiens VAMP (vesicle-associated membrane protein)-associated protein A. PPP2R4 = Homo sapiens protein
phosphatase 2 (formerly 2A), regulatory subunit 4; CLDN = claudin mRNA; CTNNA1and B1 Catenin (cadherin-associated protein) alpha1and beta 1;
ERBB2 = erythrobalstic leukaemia viral oncogene homolog2, neuro/glioblastoma derived oncogene homolog (avian), transcript variant 2, mRNA; MLLT4 =
myeloid leukemia/lymphoid or mixed linage leukaemia; translocated to, 4, transcript variant 3, mRNA
* 14 other variants of PPP2A were also signiﬁcantly upregulated with ABC 6 months compared to the combined AZT and TDF group (p = 0.009–6.8E–10)
** 4 other variants of PPP2A were upregulated (p = 7.0E–10 to p = 0.003) and 6 variants down regulated (p = 0.0001–0.003)
Pathways: AJ = adherence junction; CAM = cell adhesion molecule; CCR = cytokine-cytokine receptor interaction; NFkB = NF kappa B; LTM = leukocyte
transendothelial migration; TJ = tight junction; TLR = toll-like receptors
doi:10.1371/journal.pone.0117164.t005
Abacavir Regimen and Adherence Junction Genes
PLOS ONE | DOI:10.1371/journal.pone.0117164 January 24, 2015 9 / 18
enriched at 18–24 months against the treatment naïve patients were 27, 17 and 15 for ABC,
TDF and AZT respectively. A selected list of GO terms relating to cell adhesion comparing
controls with the three treatment groups as well as between group comparisons are shown in
Table 6. Compared to controls 48 and 17 genes controlling GO terms ‘cell junction assembly’
and ‘apical junction’ respectively were up-regulated and 17 and 4 genes were down-regulated
(p<0.01). Similarly, for GO term ‘cell adhesion’, 172 genes were up-regulated and 17 were
down-regulated in ABC-treated patients for 6 months compared to controls.
A complete list of Kegg pathways that are enriched for all three treatment groups at different
times after initiating treatment compared to controls is shown on Table 7.
e. Validation of microarray
In order to validate the microarray study we looked at genes that we had previously shown to
be significantly up or down-regulated in the adipose tissue by real time PCR on the same
subcutaneous fat samples. [19,20] Thus we found that compared to the controls hexose 6-
phosphate dehydrogenase (H6PD) was up-regulated (fold change 4.1, p<0.0001) in the AZT
treated group as was also found with PCR. Expression of 11-beta hydroxysteroid dehydroge-
nase-1 (11βHSD-1) was down-regulated compared pre-treatment expression for both AZT
and TDF (p = 0.001 and p<0.01 respectively) in keeping with real time PCR. Similarly, uncou-
pling protein 2 (UCP-2) was up-regulated for AZT treatment group at 18–24 months (p =
0.009) compared to pre-treatment values and UCP-3 down-regulated for both AZT and TDF
(p = 0.007 and p = 0.004 respectively), as previously reported for PCR. Cytochrome BB
(CYBB) and cytochrome B5 were down-regulated (p = 0.03 and p = 0.009 respectively) after
18–24m AZT treatment. Moreover CYBB was significantly up-regulated in the TDF 18–24m
group compared to AZT treatment after 18–24 m (p = 0.001). These findings confirm our
previous report that treatment with AZT, compared to TDF appears to impair mitochondrial
oxygen transport genes.[19,20]
Biological validation also comes from the observation that KEGG pathway enrichment was
observed for fatty acid metabolism (TDF, p = 0.04), glycolysis and gluconeogenesis (TDF, p =
0.04), and steroid hormone biosynthesis (AZT, p = 0.03) at six months. At 18–24 months after
Table 6. Selected GO terms relating to cell adhesion.
Go term Go
ref
Cont vs
ABC 6m
Cont vs
AZT 6m
ABC vs
AZT 6m
ABC vs TDF
6m
Cont vs ABC
18–24m
Cont vs AZT
18–24m
Cont vs TDF
18–24m
Biological adhesion 22610 OR 1.3 p =
0.03
OR 1.3 p =
0.01
OR 1.3 p =
0.009
OR 1.5 p =
0.0008
Cell adhesion 7155 OR 1.3 P =
0.03
OR 1.3 p =
0.01
OR 1.2 p = 0.07 OR 1.5 p =
0.0009
Cell-cell adhesion 16337 OR 1.4 p =
0.04
OR 2.3 p =
0.04
OR 1.4 p =
0.03
OR 1.5 p = 0.01 OR 1.5 p = 0.02
Regulation of cell-cell
adhesion
22407 OR 1.9 p =
0.04
OR 7.2 p =
0.04
OR 1.7 p =
0.02
OR 1.8 p = 0.04 OR 2.0 p =
0.026
OR 1.9 p =
0.035
Apical junction
assembly
43297 OR 2.8 p =
0.02
OR 2.0
p<0.04
Cell-cell junction
assembly
7043 OR 1.8 p =
0.4
OR 1.8 p =
0.04
OR 1.4 p = 0.04
Cell-cell junction
organisation
45216 OR 1.4 p =
0.04
None of the GO terms appeared for control vs TDF at 6 months. Cont = control; GO ref = GO term reference; m = months on treatment; OR = odds ratio;
p = adjusted p value
doi:10.1371/journal.pone.0117164.t006
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Table 7. KEGG gene pathways signiﬁcantly enriched compared to HIV negative controls.
Treatment Time KID Term Expected
Count
Cnt OR P
value
adjusted P
value
Control—
ABC
6 m 604 Glycosphingolipid biosynthesis—ganglio series 2.89 8 6.35 0.0021 0.0189
5412 Arrhythmogenic right ventricular cardiomyopathy
(ARVC)
13.48 23 2.23 0.0034 0.0189
4512 ECM-receptor interaction 16.37 25 1.86 0.0124 0.0363
510 N-Glycan biosynthesis 11.07 18 2.05 0.0161 0.0363
600 Sphingolipid metabolism 7.46 13 2.29 0.0210 0.0363
4510 Focal adhesion 41.15 53 1.44 0.0212 0.0363
4622 RIG-I-like receptor signaling pathway 11.55 18 1.91 0.0255 0.0363
3450 Non-homologous end-joining 2.65 6 3.80 0.0285 0.0363
4360 Axon guidance 24.31 33 1.55 0.0297 0.0363
4530 Tight junction 24.07 32 1.50 0.0423 0.0433
4520 Adherens junction 16.37 23 1.63 0.0433 0.0433
Control—
ABC
18–24 m 4360 Axon guidance 24.05 40 2.14 0.0003 0.0034
510 N-Glycan biosynthesis 10.95 19 2.28 0.0062 0.0404
4141 Protein processing in endoplasmic reticulum 35.95 48 1.52 0.0142 0.0457
600 Sphingolipid metabolism 7.38 13 2.33 0.0192 0.0457
62 Fatty acid elongation in mitochondria 1.90 5 5.35 0.0221 0.0457
3450 Non-homologous end-joining 2.62 6 3.86 0.0271 0.0457
4310 Wnt signaling pathway 27.14 36 1.49 0.0341 0.0457
2010 ABC transporters 7.14 12 2.15 0.0354 0.0457
5200 Pathways in cancer 63.34 76 1.30 0.0371 0.0457
4520 Adherens junction 16.19 23 1.65 0.0387 0.0457
4512 ECM-receptor interaction 16.19 23 1.65 0.0387 0.0457
604 Glycosphingolipid biosynthesis—ganglio series 2.86 6 3.21 0.0435 0.0462
4610 Complement and coagulation cascades 11.43 17 1.77 0.0462 0.0462
Control—AZT 6m 5332 Graft-versus-host disease 0.43 3 8.08 0.0084 0.0300
4020 Calcium signaling pathway 1.98 6 3.34 0.0136 0.0300
4970 Salivary secretion 0.97 4 4.55 0.0155 0.0300
4060 Cytokine-cytokine receptor interaction 2.17 6 3.03 0.0206 0.0300
5014 Amyotrophic lateral sclerosis (ALS) 0.62 3 5.37 0.0231 0.0300
4210 Apoptosis 1.13 4 3.86 0.0258 0.0300
512 Mucin type O-Glycan biosynthesis 0.31 2 7.26 0.0373 0.0373
Control—AZT 18–24 m 4080 Neuroactive ligand-receptor interaction 26.07 54 2.78 0.0000 0.0000
4950 Maturity onset diabetes of the young 3.05 10 6.20 0.0002 0.0017
4020 Calcium signaling pathway 22.86 36 1.83 0.0025 0.0108
5410 Hypertrophic cardiomyopathy (HCM) 10.67 20 2.32 0.0027 0.0108
4975 Fat digestion and absorption 4.91 11 3.03 0.0055 0.0176
5014 Amyotrophic lateral sclerosis (ALS) 7.11 14 2.48 0.0070 0.0188
4142 Lysosome 18.29 28 1.75 0.0110 0.0198
4930 Type II diabetes mellitus 6.77 13 2.39 0.0117 0.0198
4340 Hedgehog signaling pathway 6.10 12 2.48 0.0122 0.0198
4060 Cytokine-cytokine receptor interaction 25.06 36 1.61 0.0124 0.0198
4740 Olfactory transduction 7.11 13 2.22 0.0179 0.0260
531 Glycosaminoglycan degradation 2.37 6 3.70 0.0204 0.0271
(Continued)
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treatment PPAR signalling pathway (OR 5.4, p = 0.023) and biosynthesis of fatty acids (OR 9.2,
p = 0.026) were enriched in all three treatment groups, an observation in keeping with return
to health reported in many studies, and the observed increase in limb and central fat in the first
24 weeks of antiviral therapy.[28] The consistency of the direction of changes in individual
genes in the cross-sectional comparisons across the treatment groups at both time intervals
(Table 6) strengthens further the validity of the study.
Discussion
In this study we generated microarray data from mRNA prepared from subcutaneous fat sam-
ples from HIV negative controls, treatment naïve HIV infected individuals, and after 6 months
and 18–24 months into their initial antiretroviral treatment. The regimens contained AZT,
TDF or ABC in combination tablets with lamivudine or emtricitabine. All three regimens also
Table 7. (Continued)
Treatment Time KID Term Expected
Count
Cnt OR P
value
adjusted P
value
983 Drug metabolism—other enzymes 4.57 9 2.47 0.0285 0.0347
4512 ECM-receptor interaction 11.51 18 1.79 0.0304 0.0347
4974 Protein digestion and absorption 9.31 15 1.86 0.0358 0.0382
4380 Osteoclast differentiation 18.45 26 1.56 0.0383 0.0383
Control—
TDF
6m 310 Lysine degradation 0.16 2 14.9 0.0106 0.0388
4621 NOD-like receptor signaling pathway 0.19 2 11.98 0.0156 0.0388
4060 Cytokine-cytokine receptor interaction 0.59 3 6.10 0.0192 0.0388
5131 Shigellosis 0.22 2 10.6 0.0194 0.0388
53 Ascorbate and aldarate metabolism 0.04 1 33.3 0.0352 0.0417
4210 Apoptosis 0.31 2 7.46 0.0364 0.0417
4666 Fc gamma R-mediated phagocytosis 0.33 2 6.99 0.0408 0.0417
4650 Natural killer cell mediated cytotoxicity 0.33 2 6.90 0.0417 0.0417
Control—
TDF
18–24 m 4080 Neuroactive ligand-receptor interaction 25.03 51 2.67 0.0000 0.0000
4610 Complement and coagulation cascades 7.80 20 3.76 0.0000 0.0002
4020 Calcium signaling pathway 21.94 37 2.00 0.0006 0.0030
4930 Type II diabetes mellitus 6.50 14 2.81 0.0029 0.0100
4060 Cytokine-cytokine receptor interaction 24.06 37 1.76 0.0036 0.0100
4975 Fat digestion and absorption 4.71 11 3.18 0.0040 0.0100
4512 ECM-receptor interaction 11.05 19 2.03 0.0099 0.0213
4974 Protein digestion and absorption 8.94 16 2.14 0.0116 0.0218
4950 Maturity onset diabetes of the young 2.93 7 3.30 0.0179 0.0276
5217 Basal cell carcinoma 5.69 11 2.38 0.0191 0.0276
5410 Hypertrophic cardiomyopathy (HCM) 10.24 17 1.93 0.0202 0.0276
4370 VEGF signaling pathway 10.40 17 1.89 0.0235 0.0294
4740 Olfactory transduction 6.83 12 2.08 0.0310 0.0351
604 Glycosphingolipid biosynthesis—ganglio series 1.95 5 3.70 0.0327 0.0351
4310 Wnt signaling pathway 18.53 26 1.54 0.0407 0.0407
KID = Kegg identity; Cnt = actual count, OR = odds ratio; Time = time after treatment
doi:10.1371/journal.pone.0117164.t007
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contained efavirenz. The patients were matched for age, ethnicity, sex and pre-treatment CD4
count and viral loads. None had experienced any AIDS defining conditions.
We have shown that at all time points patients receiving ABC displayed a markedly different
pattern of gene expression within subcutaneous adipose tissue, with a large percent of the over-
all variance accounted for by ABC compared to the other two treatment groups. The differ-
ences were particularly marked at 6 months after treatment initiation but were still evident at
18–24 months. After 6 months of treatment, 4185 genes showed significant differentially ex-
pressed sequences (DET) in patients receiving ABC relative to the controls while the number
of DETs in the AZT and the TDF group were 895 and 381 respectively. After 18–24 months of
treatment the differences between the three groups had narrowed. (Table 1)
We next examined the specific pathways over expressed in the three treatment groups com-
pared to controls and to treatment naïve HIV-infected patients. All groups showed an enrich-
ment of PPAR signalling and biosynthesis of fatty acids in agreement with previous studies of
the effect of antiretroviral therapy [19,20,29,30] and a return to health.[8,28] The ABC group,
however showed enrichment of a number of pathways at both time points that was not ob-
served with the other two groups. The pathways of interest are involved with cell processes and
cell communication (adherence junction, focal adhesions, tight junctions) and environmental
information processing (WNT signalling, ECM receptor interaction, leukocyte transendothelial
migration, neuroactive ligand interactions, MAPK signalling). Some of these may have
important roles in cardiovascular disease.[31–35]
With the greatly increase survival observed with the use of combination anti-retroviral
therapy long term complications of such therapies have assumed increasing importance. HIV
itself [36] and antiviral treatments are associated with an increased incidence of cardiovascular
disease [10] which is not entirely explained by traditional risk factors including adjustment for
lipids [11]. In large cohort studies the increased risk of cardiovascular disease was associated
with the use of protease inhibitors [10] and current or recent use of ABC and less consistently,
didanosine.[10–14,18] Pooled analysis of two cohort studies [11,14] demonstrated a relative
risk of 1.91 (95% CI: 1.5, 2.4) for use of ABC within previous six months and risk of myocardial
infarction [37]. Other cohort studies [18,38] or randomised control trials (RCT) [16,39] have,
on the other hand, not confirmed the association between ABC and cardiovascular events. Pa-
tients recruited in RCT, however, tend to be younger and followed for a shorter period of time
than cohort studies. Hence despite their limitations results from large cohort studies cannot be
entirely ignored [37]. Current International AIDS Society – USA Panel guidelines [40] advise
avoidance of ABC use in patients at high risk of cardiovascular disease.
Possible mechanisms for the cardiovascular effects of ABC include an association with in-
flammatory markers,[41–43] abnormalities in endothelial cell function, [32,44] and platelet
dysfunction. [45–48] These results have not been confirmed by other studies.[49–52] Thus the
potential role of ABC in cardiovascular disease and the possible mechanisms through which
this can be effected remain to be established.
The observation that the increased risk of cardiovascular events was only seen with recent
or current use of ABC,[11,14,18,41] particularly in those in the higher Framingham risk group
[11] suggests an additive effect of ABC to an already pre-existing underlying pathological
mechanisms such as plaque instability, endothelial function, or thrombosis.[53] Our study pro-
vides another possible mechanism that requires further research. Tight junctions (TJ) focal ad-
hesions and adherence junctions (AJ) were overrepresented in the KEGG pathway and
‘biological adhesions’ in GO terms 6 months after ABC treatment. In particular TJ and AJ are
interlinked and important for maintaining tissue architecture [33,54,55] and have been impli-
cated in cardiovascular disease. The gene VE-cadherin at AJ up-regulates TJ gene claudin-5 by
limiting the nuclear accumulation of beta-catenin, which represses the claudin-5 promoter.
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[54] We showed down regulation of claudin-5 (CLDN5) and up-regulation of catenins
(CTNNA1, CTNNB1) compared to controls and to AZT and TDF at 6 months (Tables 3 and
5) while there was no observable change in the expression of VE-cadherin (data not shown).
These changes may result in increased endothelial permeability in subcutaneous adipose tissue
in patients treated with ABC.[54] Were such time related changes in vascular permeability to
be replicated in other tissues, and in particular coronary vasculature, an additional possible
mechanism for the observed increase in the incidence of cardiovascular disease in patients
starting abacavir treatment with underlying cardiovascular risk would be suggested. Further
studies could provide insight into this suggested mechanism.
Pathways involved with environmental information processing (ECM-receptor interactions,
MAPK signalling, neuroactive ligand interaction, Wnt signalling pathway) tended to be either
enriched earlier in ABC (Table 2) or were significantly different at 6 months (Tables 4 and 5)
and GO term ‘biological adhesions’ ‘cell adhesion’ and ‘cell matrix adhesion’, ‘cell-cell signal-
ing’ and ‘signaling’ were overrepresented in the ABC group compared to the other two groups.
Cell adhesion molecules (CAMs) [31,33] and inflammatory markers are also believed to
play an important role in atherosclerosis. However, reports of abnormalities in circulatory
CAMs and inflammatory markers in endothelial function after ABC treatment are conflicting.
[42,42,44,51,52,56–58] as are the nature of the relationship between circulating inflammatory
markers and the expression of adhesion molecules at the endothelial surface.[34,59,60]
De Pablo et al. reported that ABC significantly induces leucocyte accumulation through ac-
tivation of MAC-1 which reacts with its endothelial ligand ICAM-1 both in vitro and in vivo
[56,61]. The demonstration of enrichment of genes involved with leukocyte transendothelial
migration (Table 4) and up-regulation of ICAM 1, ICAM-4 and ICAM-5 compared to controls
and, in the case of the latter two compared to the other two groups, after six-month ABC treat-
ment (Table 5) are compatible with these findings.
Our study does have several limitations. Patients receiving AZT and TDF were randomised
while those on ABC were only matched as to gender and ethnicity. While there was no statisti-
cal difference in weight (pre-treatment and at test), BMI, CD4 count, smoking history, and
family history of diabetes and cardiovascular disease between the three groups, an unintended
bias cannot be excluded. Moreover the number of subjects in each treatment group was neces-
sarily small, and not all subcutaneous fat samples were available for study, further limiting the
conclusions. However we adjusted for multiple comparisons by using the Benjamini-Hochberg
False Discovery Rate (FDR) as well as Bonferroni multiple testing corrections. Finally as dis-
cussed above any extrapolation for gene expression from samples obtained from one tissue
must only be guardedly extended to the whole subject, not least because we were unable to
comment on post-transcriptional and regulation or post-translational modifications of gene
expression.
Our study has highlighted novel mechanisms by which ABC may interfere with endothelial
adhesion process and endothelial function in subcutaneous adipose tissue, particularly early in
the treatment. In particular abnormalities in tight junction and adherence junction brought
about by ABC use, if observed in other tissues, may be a contributing factor to cardiovascular
events in persons already with some underlying risk for atherosclerosis[62], and may require
further study.
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